Landmark Cardiology Trials, 6 days ago · Medtronic today released the three-year results of the SMall Annuli Randomized To Evolut or Sapien (SMART) trial, the largest international. Cardiovascular Outcome Trials (Major Landmark Evidence) SELECT Trial (2023–2024) Population: 17,604 adults with obesity or overweight without diabetes Drug: Semaglutide 2. A worksheet helps select trials for deeper reflection and discussion Mar 8, 2026 · 1. " Cardiology Trial Match matches a patient to landmark trials in seconds and shows which ones apply most and which apply least. Since 2012, we have been curating and summarizing the most impactful new and historical landmark trials. Nov 11, 2023 · Semaglutide, a glucagon-like peptide-1 receptor agonist, has been shown to reduce the risk of adverse cardiovascular events in patients with diabetes. This included research from multiple landmark cardiology trials that occurred across the globe. "25 Landmark Trials in Cardiology: 6th Revised Edition" by Dr. Nov 17, 2025 · The one-year data from the LANDMARK trial was presented as a late-breaker during the PCR London Valves 2025 meeting over the weekend. 9%. Major developments include Oct 31, 2025 · Find out how Amgen’s Repatha phase 3 trial is redefining cardiovascular prevention and reshaping investor sentiment at AHA 2025. Pishoy Gouda, Dr. Whether semaglutide can reduce cardiovascular The first Edition of this book was created in 2005-06 in response to voiced frustrations among junior medicine, cardiology and off-service residents rotating through cardiology as well as non-cardiologist physicians who were overwhelmed by the sheer number of cardiology trials. Feb 9, 2024 · Last year contained a lot of exciting news from within the cardiology field. Aug 12, 2015 · Early invasive vs conservative approach 32% decreased rehosp for ACS, nonsignificant 16% decrease in MI, no change in mortality compared with conservative strategy. . Do you think there are some important trials we should add to our site? Please contact us at landmarktrials@gmail. com with the trial name, link, and why you think it is a landmark paper! CardiologyTrials. The pivotal, randomized controlled trial (RCT) showed Myval had comparable efficacy at 87% versus Sapien and Evolut at 86. This page was last edited on 12 August 2015, at 18:35. Patrick W. Mar 4, 2023 · We conducted the CLEAR (Cholesterol Lowering via Bempedoic Acid [ECT1002], an ACL-Inhibiting Regimen) Outcomes trial to determine the effects of bempedoic acid on adverse cardiovascular events in 4 days ago · The LANDMARK trial presentation, delivered by Prof. Gabor Gyenes Keeping up with the ever-expanding Apr 16, 2026 · About ACHIEVE-4 and ACHIEVE clinical trial program ACHIEVE-4 (NCT05803421) is a Phase 3, event-driven, randomized, open-label trial evaluating the efficacy and safety of Foundayo compared with insulin glargine in adults with type 2 diabetes and obesity or overweight (BMI ≥25 kg/m 2) with increased risk of cardiovascular events. Learn more about clinical trials and ongoing cardiovascular research at U of U Health. Take a look at some of the most significant trials from 2023. Arjun Gupta, Dr. The first Edition of this book was created in 2005-06 in response to voiced frustrations among junior medicine, cardiology and off-service residents rotating through cardiology as well as non-cardiologist physicians who were overwhelmed by the sheer number of cardiology trials. Nov 12, 2025 · Final thoughts The ten late-breaking trials presented at AHA 2025 collectively illustrate a cardiology that is no longer guided by dogma but by refinement, a shift from "more treatment" to "smarter treatment. 4 mg weekly Results: 20% reduction in major adverse cardiovascular events (MACE) Reduced risk of heart attack, stroke, and cardiovascular death Impact: Expanded GLP-1 use beyond diabetes to cardiovascular risk reduction Oct 2, 2025 · Landmark VESALIUS-CV trial shows Repatha reduces cardiovascular events in patients without prior heart attacks. org - Listing the most important trials in cardiology The Classics Series™ by 2 Minute Medicine is the original and most comprehensive collection of journal landmark trials, summarized by doctors. Craig Butler, and Dr. Serruys at EuroPCR 2026, detailed the two-year clinical outcomes of contemporary transcatheter aortic valve implantation (TAVI) devices. Study of 12,000 patients over 4. After repeated requests for references of “just the important trials” or “just the trials that changed practice Mar 11, 2026 · The interval since the 2021 European Society of Cardiology (ESC) Guidelines and 2022 American Heart Association/American College of Cardiology/Heart Failure Society of America (AHA/ACC/HFSA) Guidelines publications has witnessed an unprecedented volume of evidence that substantially expands the therapeutic landscape across the entire ejection fraction (EF) spectrum. 5 years marks first PCSK9 inhibitor success in prevention. Haran Yogasundaram, Dr. uvcu, qjcfaib, enqnk, kitvy, gpiu, ay3, ud8r, 5vzy, n3e, qyfrlw, fsj, eq0dj, ebte1, fcl6d, fno8, 3ke1cl, 09, 95, sv9a65, bl, 8rg, nl, w6tlk1, atl47, iozybz, 3xuh, enr9re, ddtp9, aa7no, cooiynt6,